Penn Medicine pathologists pioneer biomarker test to diagnose or rule out Alzheimer's disease

March 17, 2009

Biomarker signatures predict conversion from mild cognitive impairment to Alzheimer's disease

PHILADELPHIA, PA - A test capable of confirming or ruling out Alzheimer's disease has been validated and standardized by researchers at the University of Pennsylvania School of Medicine. By measuring cerebrospinal fluid (CSF) concentrations of two of the disease's biochemical hallmarks - amyloid beta42 peptide and tau protein - the test also predicted whether a person's mild cognitive impairment would convert to Alzheimer's disease over time. Researchers were able to detect this devastating disease at the earliest stages, before dementia symptoms appeared and widespread irreversible damage occurred. The findings hold promise in the search for effective pharmaceutical therapies capable of halting the disease.

Honing in on a previously suggested pathological CSF biomarker signature, a team of Penn Medicine researchers, led by Leslie M. Shaw, PhD, Co-Director of the Penn Alzheimer's Disease Neuroimaging Initiative (ADNI) Biomarker Core, found evidence of neuron degeneration - marked by an increase in CSF concentration of tau proteins - and plaque deposition, indicated by a decrease in amyloid beta42 concentration. In addition, people with two copies of the genetic risk factor for Alzheimer's disease, APOE ε4 , had the lowest concentrations of amyloid beta42, compared to those with one or no copies. The study appears in the online edition of the Annals of Neurology.

"With this test, we can reliably detect and track the progression of Alzheimer's disease," said Dr. Shaw. "Validated biomarker tests will improve the focus of Alzheimer's clinical trials, enrolling patients at earlier stages of the disease to find treatments that can at least delay -and perhaps stop- neurodegeneration. In addition, prevention trials can test methods to delay or block mild cognitive impairment from converting to full-blown Alzheimer's."

Further validation studies of this research test system are underway. Additional work is needed to develop additional biomarkers, as well as identify more genetic risk factors that will help distinguish Alzheimer's from other neurodegenerative diseases characterized by cognitive impairments.

"Thanks to the dedicated researchers and volunteers who participated in this and other Alzheimer's disease studies through the Penn Alzheimer's Disease Core Center and at ADNI trial sites around the US and Canada, we have validated a test where a safe, simple lumbar puncture can provide information to confirm suspected Alzheimer's disease and predict the onset of the disease," said John Q. Trojanowski, MD, PhD, Director of the Penn Alzheimer's Disease Core Center. "Using this technique, we will further our understanding of how the disease progresses and what we can do to stop Alzheimer's disease before it starts."

About the Study

Cerebral spinal fluid samples contributed by 410 ADNI volunteers at 56 sites across the U.S. and Canada were included in this study. To independently establish threshold values for these biomarkers, cerebrospinal fluid samples from 52 Penn Memory Center volunteers with normal cognition and 56 people with confirmed Alzheimer's disease based on post-mortem autopsy diagnosis were also measured. The test was based on the multiplexed xMAP microbead immunoassay system, with reagents provided by Innogenetics.

When compared with normal, healthy adults of the same age, a pattern of changes emerged in people with mild cognitive impairment or Alzheimer's disease. In this group, tau concentrations increased, while amyloid beta42 levels decreased as the disease progressed.

* The test was 87 percent accurate overall (80 percent or above is considered clinically useful).
* In the CSF samples from those with autopsy-confirmed Alzheimer's disease, the amyloid beta42 concentration threshold was most sensitive and detected Alzheimer's disease at a rate of 96.4 percent.
* The test accurately ruled out Alzheimer's disease in 95.2 percent of the subjects.
* The test positively predicted the conversion from mild cognitive impairment to Alzheimer's disease at a rate of 81.8 percent.

Data used in preparing this article were produced by the Alzheimer's Disease Neuroimaging Initiative (ADNI) Biomarker Core at Penn or obtained from the ADNI database (www.loni.ucla.edu/ADNI). Many ADNI investigators contributed to the design and implementation of ADNI or provided information but did not participate in the analysis of the data presented here or in the writing of this report. A complete list of ANDI investigators is available at http://www.loni.ucla.edu/ADNI/Collaboration/ADNI_Authorship_list.pdf.

University of Pennsylvania School of Medicine

---

---

	Living with Mild Cognitive Impairment: A Guide to Maximizing Brain Health and Reducing Risk of Dementia by Nicole D. Anderson (Author), Kelly J. Murphy (Author), Angela K. Troyer (Author) One in ten adults over 65 has some form of mild cognitive impairment or MCI--thinking problems that go beyond those associated with normal aging, but that fall short of the serious impairments experienced by people with Alzheimer's Disease and other dementias. This is the first book written specifically for individuals with MCI, for their loved ones, and for the health care professionals who treat them. Written by three clinicians and researchers who have devoted their careers to MCI patients, this book provides up-to-date and reliable information on the nature of this disorder, how it may affect people, and what can be done about it. The authors explain how MCI is diagnosed and treated and they offer advice on how to improve cognitive health through diet and exercise, through social...
	Assessment of Feigned Cognitive Impairment: A Neuropsychological Perspective by Kyle Brauer Boone PhD ABPP ABCN (Editor) Comprehensive and user friendly, this book synthesizes the growing literature on symptom feigning in cognitive testing and translates it into evidence-based recommendations for clinical and forensic practice. A wide range of cognitive effort assessment techniques and strategies are critically reviewed, including both dedicated measures and the use of embedded indicators in standard clinical tests. The book describes approaches to distinguishing between credible and noncredible performance in specific clinical populations: persons presenting with head injury, chronic pain and fatigue, attention-deficit/hyperactivity disorder and learning disability, mental retardation, seizures, and exposure to environmental toxins. Special topics include the potentially confounding effects of psychiatric...
	MTTC Cognitive Impairment (56) Test Flashcard Study System: MTTC Exam Practice Questions & Review for the Michigan Test for Teacher Certification by Mometrix Media LLC MTTC Cognitive Impairment (56) Test Flashcard Study System uses repetitive methods of study to teach you how to break apart and quickly solve difficult test questions on the Michigan Test for Teacher Certification. Study after study has shown that spaced repetition is the most effective form of learning, and nothing beats flashcards when it comes to making repetitive learning fun and fast. Our flashcards enable you to study small, digestible bits of information that are easy to learn and give you exposure to the different question types and concepts. MTTC Cognitive Impairment (56) Test Flashcard Study System covers all of the most important topics that you'll need to know to be successful on test day.
	Cognitive Impairment and Dementia in Parkinson's Disease by Murat Emre (Author) Parkinson's disease has long been perceived as a pure motor disorder, partly due to its initial description by James Parkinson, who suggested that "senses and intellect remain intact", and partly due to the fact that patients with PD did not survive long, before effective treatment became available. As the survival time of patients with Parkinson's disease has substantially increased due to modern treatment, it has become apparent that cognitive deficits and dementia are also frequent features, especially in elderly patients. With the progression of the disease and age, dementia develops in a substantial number of patients and constitutes a major therapeutic challenge. Dementia has thus increasingly been the focus of research and practice in recent years and a large body of knowledge has...
	Mild Cognitive Impairment: Aging to Alzheimer's Disease (Medicine) by Ronald C. Petersen (Editor) What are the boundary zones between normal aging and Alzheimer's disease (AD)? Are many elderly people whom we regard as normal actually in the early stages of AD? Alzheimer's disease does not develop overnight; the early phases may last for years or even decades. Recently, clinical investigators have identified a transitional condition between normal aging and and very early Alzheimer's disease that they have called mild cognitive impairment, or MCI. This term typically refers to memory impairment beyond what one would expect in individuals of a given age whose other abilities to function in daily life are well preserved. Persons who meet the criteria for mild cognitive impairment have an increased risk of progressing to Alzheimer's disease in the near future. Though many questions...
	The Effective Teacher's Guide to Moderate, Severe and Profound Learning Difficulties (Cognitive Impairments): Practical strategies (The Effective Teacher's Guides) by Michael Farrell (Author) This updated second edition of The Effective Teachers Guide to Moderate, Severe and Profound Learning Difficulties (Cognitive Impairments) has been restructured and expanded to ensure it continues to meet the needs of the busy teacher. This new edition is highly relevant and contextualized, drawing on the curriculum and assessment, pedagogy, resources, therapy and care and school and classroom organisation. It is accessible and practical in approach yet offers the necessary underpinning of research and professional knowledge to enable the teacher to be self-critical in developing classroom approaches. The book accessibly and thoroughly discusses the classroom difficulties associated with: Mild cognitive impairment Moderate to severe cognitive impairment Profound cognitive...
	Mild Cognitive Impairment and Early Alzheimer's Disease: Detection and Diagnosis by Jeffrey Burns (Author), John Morris (Author) Written by leading authorities in the field, this book describes the cognitive changes associated with age, the earliest detectable stages of Alzheimer’s, and the relationship of these conditions to MCI. The authors review the latest advances in our understanding of MCI, its prevalence, evaluation, management, and outcomes and in so doing provide practising physicians with a useful resource that assists them in identifying those MCI patients who will progress to recognised Alzheimer’s Disease.Beautifully presented in full colour, Early Diagnosis and Treatment of Mild Cognitive Impairment includes case studies and discusses future therapeutic and diagnostic strategies. It is an invaluable resource for postgraduates and professionals, for specialist physicians in neurology and...
	Vascular Cognitive Impairment by Timo Erkinjuntti (Author), Serge Gauthier (Author) Addressing the challenges in accurate assessment of vascular cognitive impairment and vascular disease, this book presents a collection of state-of-the-art reviews. It updates readers on the current terminology, etiology, pathophysiology, and treatment of vascular cognitive impairment. A well-written and well-illustrated definitive resource on vascular cognitive impairment, it contains 41 chapters that have been divided into five large areas: nosology, pathophysiology, clinical features, diagnosis, and course and management. The editors have assembled more than 70 contributors to create the definitive reference on the topic of vascular cognitive impairment.
	Vascular Cognitive Impairment in Clinical Practice by Lars-Olof Wahlund (Editor), Timo Erkinjuntti (Editor), Serge Gauthier (Editor) Vascular cognitive impairment is the second most common cause of dementia after Alzheimer's disease and is expected to grow in prevalence with the aging global population. The purpose of this authoritative book is to give a broad clinical perspective on vascular cognitive impairment and thus create a foundation for the implementation of good dementia care. The book focuses on pathophysiology, diagnosis, treatment and prevention. It demonstrates the underlying causes of the disorder, such as the manner in which vascular risk-factors influence the onset of vascular cognitive impairment. The concept of mixed forms of vascular dementia, Alzheimer's dementia and other vascular diseases is discussed as well as the influence of vascular changes with regard to the onset of Alzheimer's disease....
	Chemo Fog: Cancer Chemotherapy-Related Cognitive Impairment (Advances in Experimental Medicine and Biology) by Robert B. Raffa (Editor), Ronald J. Tallarida (Editor) The editors of this book are professors who are engaged in research on areas that compromise the total healing of body and mind in this patient population. One particular component of the need for survivor care is the memory problems and cognitive deficits experienced by some. The condition has been given a name––actually many names, such as chemo fog, chemo brain, and others. These names reflect the belief that the cause of the problem is the chemotherapy that they received as part of their treatment. In some cases the chemo fog/’chemo brain’ is transient while in others it is of longer duration. Little is known about this problem and that fact peaked our interest and motivated this book. Therefore this book is devoted to one aspect of survivor care: chemo fog/’chemo brain’.